



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

**NASDAQ: CELG**

Last Trade:	121.33
Trade Time:	4:15 PM ET Oct 20, 2017
Change:	-14.63 (10.761%)
Day Range	120.80 - 124.54
52-Week Range	96.93 - 147.17
Volume	27,765,072

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

**Company Profile**

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- Oct 19, 2017 [Celgene Provides Update on GED-0301 \(mongersen\) Inflammatory Bowel Disease Program](#)
- Oct 19, 2017 [Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting](#)
- Oct 16, 2017 [Results from Phase 2 Studies of Oral Ozanimod in Crohn's Disease and Ulcerative Colitis to Be Presented at World Congress of Gastroenterology at ACG2017](#)
- Oct 2, 2017 [Celgene Corporation to Announce Third Quarter 2017 Results on October 26, 2017; Will Host an Investor Webcast Event from the MSParis2017-7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017](#)
- Sep 8, 2017 [Data Presented at ESMO 2017 Further Evaluate Role of ABRAXANE® for Patients with Historically Challenging Cancers](#)

**Upcoming Events** [\[ View all \]](#)

- Oct 26, 2017 9:00 AM ET [Celgene Corporation Q3 2017 Celgene Corp. Earnings Conference Call](#)
- Oct 28, 2017 12:00 PM ET [Celgene Event at ECTRIMS](#)
- Feb 10, 2017 [Annual Report \(10-K\)](#)
- Apr 27, 2017 [Proxy Statement \(DEF 14A\)](#)
- Jul 27, 2017 [Quarterly Report \(10-Q\)](#)
- Apr 27, 2017 [Quarterly Report \(10-Q\)](#)
- Oct 27, 2016 [Quarterly Report \(10-Q\)](#)

**Financials** [\[ View all \]](#)